ReviewCardiovascular diabetology. Endocrinology reports2026
Prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia: a systematic review and meta-analysis.
Review in Cardiovascular diabetology. Endocrinology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperuricemia is one of the driving factors for the onset and progression of cardiovascular diseases, type 2 diabetes and hypertension. However, hyperuricemia is not measured regularly for these patients, and its worsening effect is underestimated. Thus, this systematic review and meta-analysis aimed to determine the pooled magnitude of hyperuricemia among patients with non-communicable diseases in Ethiopia. METHODS AND MATERIALS: This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Bibliographic databases and gray literature were extensively searched for relevant articles. Eligible articles were extracted using Microsoft Excel and exported to STATA version 17 software for statistical analysis. The pooled magnitude of hyperuricemia computed with Random-effects model. Furthermore, Sensitivity and subgroup analysis was done. Heterogeneity was determined using the I
resultsA total of 2292 patients from 8 studies were included in this systematic review and meta-analysis. The overall pooled prevalence of hyperuricemia among all patients with non-communicable diseases was 34.64% (95% CI: 29.27%, 40.02%). The prevalence of hyperuricemia among patients with cardiovascular diseases was 42.15% (95% CI: 38.08, 46.21), hypertension 34.79% (95% CI: 20.16, 49.42) and type 2 diabetes 30.87% (95% CI: 24.54, 37.20). The highest prevalence was found in Amhara region (36.73%, 95% CI: 26.12, 47.33), and the lowest was in Central Ethiopia (32.01%, 95% CI: 22.68, 41.34). The magnitude of hyperuricemia among females and males was 34.71% (95% CI: 27.79, 41.63) and 34.51% (95% CI: 29.91, 39.10) respectively. Hyperuricemia among participants aged < 45 years and > 45 years was 27.33% (95% CI: 19.82, 34.85) and 39.68% (95% CI: 34.08, 45.29) respectively.
conclusionThis systematic review and meta-analysis showed high prevalence of hyperuricemia among patients with non-communicable diseases. Therefore, regular monitoring of uric acid level is required to prevent its pathophysiological role in patients with non-communicable diseases. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (2025: CRD420251174980).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.